
Nasal tanning sprays linked to skin cancer, trading standards officers warn
Demand for these 'dangerous and unregulated' tan-enhancing sprays, which is being driven by influencers on social media, could mirror the rapid rise of youth vaping, the Chartered Trading Standards Institute (CTSI) said.
The sprays contain substances such as melanotan 2 – a synthetic hormone not approved for use in the UK – which can cause nausea, vomiting, high blood pressure, kidney problems, and an increased risk of melanoma skin cancer.
The sprays are designed to be applied to the nostrils, where they deliver melanotan 2 directly into the body. This chemical stimulates the production of melanin, which darkens the skin, and while it can supposedly work without UV exposure, its effects are enhanced when used alongside sun exposure or tanning sun beds.
Trading standards officers also raised concerns over the rise of flavoured nasal tanning sprays, which include peach, bubble gum and lime, which may make them more attractive to young people.
The self-tan market was valued at £582.2m and is projected to grow to £746.3m by 2027, according to THG Labs' Sunless Tanning Trend Report, raising concerns that nasal tanning sprays could capitalise on this booming demand, despite the health risks.
Videos on social media show tanned users promoting the products. The CTSI said many of these 'unscrupulous sellers' are also marketing tanning drops and tanning gummies, designed to be ingested.
Richard Knight, the lead officer for cosmetics and beauty at CTSI, urged consumers to question the claims made by influencers online, warning that many may not fully understand the risks themselves.
He said: 'Unlike cosmetic products, nasal tanning sprays are unlikely to have had expert safety assessment, and use of relevant health warnings and instructions for safe use are rare. This means that no one, including influencers, can truly know the risks of using these quasi-medical potions.'
Although it is illegal to sell medicinal products containing melanotan 2 in the UK, the tanners are marketed as cosmetics, meaning they fall outside the regulatory remit.
The products, which often have no ingredients list, are usually sold for about £20 each, with 'extreme flavoured nasals' marketed at £30 each and cheaper alternatives for as little as £25 for two.
Users have reported severe allergic reactions to the products, and there have been cases of hospitalisation.
Edith Eagle, from King's Lynn in Norfolk, was admitted to hospital after she suffered a serious reaction to a nasal tanning spray she bought online.
She bought the product hoping that they would give her a quick and easy sun-kissed look ahead of her holiday in April 2023, but told the BBC she felt as if she was 'suffocating' and 'drowning inside her own body'.
Knight said Eagle's story should be a cautionary tale of 'what can happen when putting unregulated products into our bodies'.
Susanna Daniels, the chief executive of Melanoma Focus, said: 'We're becoming increasingly concerned about the use of both nasal tanning sprays and tanning injections and their potential links with melanoma skin cancer.
'These unregulated and illegal products not only pose serious health risks but also encourage harmful behaviours, particularly among young consumers. We urge the public to consider the long-term impacts on their health and avoid using these substances altogether.'
The CTSI advised consumers to opt for safer self-tanning options, like lotions or sprays applied to the skin, which are regulated under the UK Cosmetics Regulation and come with clear user guidelines.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
25 minutes ago
- The Independent
Pharmacy warning of unsustainable demand for weight loss medication
The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'


Reuters
an hour ago
- Reuters
Roche to investigate whether new drug can delay or prevent Alzheimer's disease
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.


Reuters
2 hours ago
- Reuters
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.